Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-12-2013 | Review

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients

Authors: Andreas Hochhaus, Hagop Kantarjian

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2013

Abstract

Purpose

Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR–ABL-targeted TKI that inhibits BCR–ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed.

Methods

This is a review of the relevant literature regarding dasatinib development in CML (2003–2013).

Results

Dasatinib demonstrates efficacy against most BCR–ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported.

Conclusion

Dasatinib is an effective treatment option for patients with CML.

Apperley JF, Cortes JE, Kim DW et al (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. J Clin Oncol 27:3472–3479CrossRefPubMed

Baccarani M, Rosti G, Saglio G et al (2008) Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). [abstract 450]. Blood 112

Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013 June 28 [Epub ahead of print]

Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114:5426–5435CrossRefPubMed

Brave M, Goodman V, Kaminskas E et al (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14:352–359CrossRefPubMed

Bristol-Myers Squibb (2013a) Open-label study evaluating dasatinib therapy discontinuation in patients with chronic phase chronic myeloid leukemia with stable complete molecular response (DASFREE). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://www.clinicaltrials.gov/ct2/show/NCT01850004. Accessed 6 June 2013

Bristol-Myers Squibb (2013b) Phase IIb study of dasatinib versus imatinib in patients with CML-CP who have not achieved an early optimal response to imatinib (early switch). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT01593254. Accessed 26 April 2013

Bristol-Myers Squibb (2013c) Studying first line treatment of chronic myeloid leukemia (CML) in a real-world setting (SIMPLICITY). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT01244750. Accessed 26 April 2013

Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL (2005) Comparative analysis of two clinically active BCR–ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102:3395–3400CrossRefPubMedCentralPubMed

Chang Q, Jorgensen C, Pawson T, Hedley DW (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99:1074–1082CrossRefPubMedCentralPubMed

Cortes J, Rousselot P, Kim DW et al (2007a) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207–3213CrossRefPubMed

Cortes J, Jabbour E, Kantarjian H et al (2007b) Dynamics of BCR–ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005–4011CrossRefPubMed

Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:2176–2183CrossRefPubMed

Cortes J, Talpaz M, Bixby D et al (2010a) A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. [abstract 210]. Blood 116

Cortes JE, Jones D, O’Brien S et al (2010b) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398–404CrossRefPubMedCentralPubMed

Das J, Patmanabha R, Chen P et al (2005) Cyclic protein tyrosine kinase inhibitors. US patent number 006596746-B1. Patent issued July 22, 2003

Das J, Chen P, Norris D et al (2006) 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 49:6819–6832CrossRefPubMed

de Lavallade H, Apperley JF, Khorashad JS et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358–3363CrossRefPubMed

Defina M, Ippoliti M, Gozzetti A et al (2012) Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. Cancer 118:5265–5269CrossRefPubMed

Dewaele B, Floris G, Finalet-Ferreiro J et al (2010) Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 70:7304–7314CrossRefPubMed

Donato NJ, Wu JY, Stapley G et al (2003) BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690–698CrossRefPubMed

Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417CrossRefPubMed

Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 38:218–220CrossRefPubMed

European Medicines Agency (2012) Sprycel^® (dasatinib) [summary of product characteristics]. Bristol-Myers Squibb Pharma EEIG, Uxbridge, UK

Fang JC, DeMarco T, Givertz MM et al (2012) World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 31:913–933CrossRefPubMed

Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537CrossRefPubMed

Guilhot F, Apperley J, Kim DW et al (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143–4150CrossRefPubMed

Guilhot F, Kantarjian HM, Shah NP et al (2010) Dasatinib (versus imatinib) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of safety and efficacy by use of baseline medications in the DASISION trial. [abstract 2295]. Blood 116

Hanfstein B, Müller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096–2102CrossRefPubMed

Hantschel O, Rix U, Schmidt U et al (2007) The Btk tyrosine kinase is a major target of the Bcr–Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104:13283–13288CrossRefPubMedCentralPubMed

Hehlmann R, Hochhaus A, Baccarani M, European LeukemiaNet (2007) Chronic myeloid leukemia. Lancet 370:342–350CrossRefPubMed

Hennigs JK, Keller G, Baumann HJ et al (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11:30CrossRefPubMedCentralPubMed

Hiwase DK, Saunders V, Hewett D et al (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14:3881–3888CrossRefPubMed

Hiwase DK, White DL, Powell JA et al (2010) Blocking cytokine signalling along with intense Bcr–Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 24:771–778CrossRefPubMed

Hochhaus A, Kantarjian HM, Baccarani M et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303–2309CrossRefPubMed

Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200–1206CrossRefPubMed

Hochhaus A, O’Brien SG, Guilhot F et al (2009a) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054–1061CrossRefPubMed

Hochhaus A, Müller MC, Radich J et al (2009b) Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 23:1628–1633CrossRefPubMed

Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NC (2011) Impact of BCR–ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10:250–260CrossRefPubMed

Hochhaus A, Shah NP, Cortes JE et al (2012a) Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. [abstract 6504]. J Clin Oncol 30

Hochhaus A, Boqué C, Bradley Garelik MB et al (2012b) Molecular response kinetics and BCR–ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib versus imatinib: DASISION 3-year follow-up. [abstract 0192]. Haematologica 97(s1):76

Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226–2238CrossRefPubMed

Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423–1432CrossRefPubMed

Jabbour E, Kantarjian HM, Quintás-Cardama A et al (2011) Impact of dose reductions and interruptions due to adverse events (AEs) on efficacy in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) patients (pts) receiving either dasatinib (D) or imatinib (IM): analysis of the DASISION trial. [abstract 2768]. Blood 118

Kantarjian H, Pasquini R, Hamerschlak N et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143–5150CrossRefPubMed

Kantarjian H, O’Brien S, Shan J et al (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112:837–845CrossRefPubMed

Kantarjian HM, Pasquini R, Lévy V et al (2009a) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136–4147CrossRefPubMed

Kantarjian H, Cortes J, Kim DW et al (2009b) Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322–6329CrossRefPubMed

Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270CrossRefPubMed

Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123–1129 (republished with permission of the American Society of Hematology, permission conveyed through Copyright Clearance Center, Inc.)

Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132CrossRefPubMed

Khorashad JS, Milojkovic D, Mehta P et al (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111:2378–2381CrossRefPubMed

Khoury HJ, Guilhot F, Hughes T, Kim DW, Cortes JE (2009) Dasatinib treatment for Philadelphia chromosome-positive leukemias. Cancer 115:1381–1394CrossRefPubMed

Khoury HJ, Cortes JE, Kantarjian H et al (2010) Safety and efficacy of dasatinib (DAS) vs. imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. [abstract 3421]. Blood 116

Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772–782CrossRefPubMed

Kreutzman A, Ladell K, Koechel C et al (2011) Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:1587–1597CrossRefPubMed

La Rosée P, Martiat P, Leitner A et al (2013) Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013 April 28 [Epub ahead of print]

Laneuville P, Baccarani M, Cortes JE et al (2011) Analysis of patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: management and outcomes. [abstract 6605]. J Clin Oncol 29

Levinson NM, Boxer SG (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 7:e29828CrossRefPubMedCentralPubMed

Li J, Rix U, Fang B et al (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6:291–299CrossRefPubMedCentralPubMed

Lombardo LJ, Francis YL, Chen P et al (2004) Discover of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658–6661CrossRefPubMed

Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437–4444CrossRefPubMed

Marin D, Hedgley C, Clark RE et al (2012a) The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy. Blood 120:291–294CrossRefPubMed

Marin D, Ibrahim AR, Lucas C et al (2012b) Assessment of BCR–ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232–238CrossRefPubMed

Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43:967–968CrossRefPubMed

Mauro MJ, Baccarani M, Cervantes F et al (2008) Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). [abstract 7009]. J Clin Oncol 26

McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573–1619 and Circulation 119:2250–2294

Montani D, Bergot E, Gunther S et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128–2137CrossRefPubMed

Müller MC, Cortes JE, Kim DW et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944–4953CrossRefPubMed

Mustjoki S, Rousselot P, Jalkanen S et al (2010) Dasatinib induces a rapid, dose-controllable mobilization of cytotoxic lymphocytes: a novel immunomodulatory effect associated with prolonged therapy responses in advanced leukemia. [abstract 1204]. Blood 116

Mustjoki S, Richter J, Barbany G et al (2011) Favorable therapeutic responses in newly diagnosed CML-CP patients induced by dasatinib are reflected at the CD34+CD38+ progenitor cell but not at the CD34+CD38- stem cell level: results from randomized NordCML006 study. [abstract 784]. Blood 118

Mustjoki S, Auvinen K, Kreutzman A et al (2013) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914–924CrossRefPubMed

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Chronic myelogenous leukemia v.4.2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

O’Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr–Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500–4505CrossRefPubMed

O’Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR–ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412CrossRefPubMedCentralPubMed

Orlandi EM, Rocca B, Pazzano AS, Ghio S (2011) Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36:e4–e6CrossRefPubMed

Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309–2315CrossRefPubMed

Pemmaraju N, Kantarjian HM, Luthra R et al (2011) Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase (CP). [abstract 1700]. Blood 118

Pene-Dumitrescu T, Smithall TE (2010) Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285:21446–21457CrossRefPubMedCentralPubMed

Philibert L, Carzola C, Peyriere H et al (2011) Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib. [abstract 476]. Fundam Clin Pharmacol 25:95

Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE (2010) Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy in unaffected in patients who develop pleural effusion. Cancer 116:377–386CrossRefPubMedCentralPubMed

Puttini M, Coluccia AM, Boschelli F et al (2006) In vitro and in vivo activity of SKI-606, a novel Src–Abl inhibitor, against imatinib-resistant Bcr–Abl+ neoplastic cells. Cancer Res 66:11314–11322CrossRefPubMed

Quintás-Cardama A, Cortes J (2009) Molecular biology of bcr–abl1-positive chronic myeloid leukemia. Blood 113:1619–1630CrossRefPubMedCentralPubMed

Quintás-Cardama A, Kantarjian H, O’Brien S et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908–3914CrossRefPubMed

Quintás-Cardama A, Cortés JE, Kantarjian H (2008) Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 8:S82–S88CrossRefPubMed

Quintás-Cardama A, Kantarjian H, Ravandi F et al (2009a) Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115:2482–2490CrossRefPubMedCentralPubMed

Quintás-Cardama A, De Souza Santos FP, Kantarjian H et al (2009b) Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115:3935–3943CrossRefPubMedCentralPubMed

Radich JP, Kopecky KJ, Appelbaum FR et al (2012) A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120:3898–3905CrossRefPubMedCentralPubMed

Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33:861–864CrossRefPubMed

Redaelli S, Piazza R, Rostagno R et al (2009) Activity of bosutinib, dasatinib and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27:469–471CrossRefPubMed

Rix U, Hantschel O, Dürnberger G et al (2007) Chemical proteomic profiles of the BCR–ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood 110:4055–4063CrossRefPubMed

Saglio G, Dombret H, Rea D et al (2008) Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. [abstract 0880]. Haematologica 93:349

Saglio G, Kim DW, Issaragrisil S et al (2010a) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 362:2251–2259CrossRefPubMed

Saglio G, Hochhaus A, Goh YT et al (2010b) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 116:3852–3861CrossRefPubMed

Saglio G, Hochhaus A, Cortes JE et al (2010c) Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. [abstract 2286]. Blood 116

Saglio G, Kantarjian HM, Shah N et al (2012) Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. [abstract 1675]. Blood 120

Sano M, Saotome M, Urushida T et al (2012) Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med 51:2337–2340CrossRefPubMed

Schiffer CA, Cortes JE, Saglio G et al (2010a) Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib. [abstract 358]. Blood 116

Schiffer CA, Cortes JE, Saglio G et al (2010b) Lymphocytosis following treatment with dasatinib with response and outcome. [abstract 6553]. J Clin Oncol 28:15sCrossRef

Serpa M, Sanabani SS, Bendit I et al (2010) Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol 4:155–162PubMedCentralPubMed

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401CrossRefPubMed

Shah NP, Skaggs BJ, Branford S et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR–ABL mutations with altered oncogenic potency. J Clin Invest 117:2562–2569CrossRefPubMedCentralPubMed

Shah NP, Kantarjian HM, Kim DW et al (2008a) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212CrossRefPubMed

Shah NP, Kasap C, Weier C et al (2008b) Transient potent BCR–ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14:485–493CrossRefPubMed

Shah NP, Kim DW, Kantarjian H et al (2010) Potent, transient inhibition of BCR–ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232–240CrossRefPubMedCentralPubMed

Shah NP, Cortes JE, Schiffer CA et al (2011) Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. [abstract 6512]. J Clin Oncol 29

Shah NP, Kantarjian H, Kim DW et al (2012) Six-year follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia receiving dasatinib. [abstract 6506]. J Clin Oncol 30

Soverini S, Martinelli G, Colarossi S et al (2006) Presence or the emergence of a F317L BCR–ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 24:e51–e52CrossRefPubMed

Soverini S, Martinelli G, Colarossi S (2007a) Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR–ABL mutants in Ph+ ALL. Lancet Oncol 8:273–274CrossRefPubMed

Soverini S, Colarossi S, Gnani A et al (2007b) Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR–ABL kinase domain. Haematologica 92:401–404CrossRefPubMed

Soverini S, Gnani A, Colarossi S et al (2009) Philadelphia-positive patients who already harbor imatinib-resistant Bcr–Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114:2168–2171CrossRefPubMed

Sprycel^® (dasatinib) capsules [prescribing information] 2013. Princeton, NJ: Bristol-Myers Squibb Company

Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531–2541CrossRefPubMed

Tasigna (nilotinib) capsules [prescribing information] 2013 East Hanover, NJ: Novartis Pharmaceuticals Corporation

Tokarski JS, Newitt JA, Chang CY et al (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790–5797CrossRefPubMed

Vajpai N, Strauss A, Fendrich G et al (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283:18292–18302CrossRefPubMed

Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP (2013) Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure—response analysis of a Phase III study. Clin Pharmacol 5:85–97PubMedCentralPubMed

Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr–Abl. Cancer Cell 7:129–141CrossRefPubMed

White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064–4072CrossRefPubMed

Wong S, Witte ON (2004) The BCR–ABL story: bench to bedside and back. Annu Rev Immunol 22:247–306CrossRefPubMed

Zhou T, Commodore L, Huang WS et al (2011) Structural mechanism of the pan-BCR–ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1–11CrossRefPubMed

Title: The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
Authors: Andreas Hochhaus
Hagop Kantarjian
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1488-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2013

Specific expression of k63-linked ubiquitination of calmodulin-like protein 5 in breast cancer of premenopausal patients

Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients

Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer

RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7)

Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion

Modulation of peripheral immune responses by paclitaxel–ifosfamide–cisplatin chemotherapy in advanced non-small-cell lung cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page